Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | METAP1 | P53582 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419203 | 0.83 | MAPK1 (0.76) | ALOX15MAPK1CYP1A2NPC1RAB9A | |
| Bromide SCHEMBL27908055 | 0.82 | MAPK1 (0.74) | ALOX15MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL714175 | 0.81 | MAPK1 (0.73) | ALOX15MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL16363830 | 0.81 | MAPK1 (1.00) | ALOX15MAPK1CYP1A2NPC1RAB9A | |
| Bromide SCHEMBL27908387 | 0.80 | CYP1A2 (0.66) | ALOX15MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL18026621 | 0.80 | ALOX15 (0.76) | ALOX15MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL4547981 | 0.80 | ALOX15 (0.48) | ALOX15MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL12673323 | 0.80 | ALOX15 (0.48) | ALOX15MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL12753549 | 0.80 | ALOX15 (0.48) | ALOX15MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL4548001 | 0.80 | ALOX15 (0.48) | ALOX15MAPK1CYP1A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | ALOX15 2365/4885MAPK1 1515/4885CYP1A2 2166/4885 |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | ALOX15 2365/4885MAPK1 1515/4885CYP1A2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.